Jayson Bedford
Stock Analyst at Raymond James
(3.81)
# 657
Out of 5,165 analysts
324
Total ratings
53.42%
Success rate
7.04%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXGN Axogen | Maintains: Outperform | $20 → $27 | $32.84 | -17.78% | 2 | Oct 30, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $592 → $603 | $483.46 | +24.73% | 9 | Oct 22, 2025 | |
| CBLL CeriBell | Initiates: Strong Buy | $19 | $19.16 | -0.84% | 1 | Oct 21, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $141 → $146 | $109.95 | +32.79% | 30 | Oct 16, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $174 → $209 | $243.19 | -14.06% | 24 | Oct 15, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $104 → $113 | $93.30 | +21.11% | 9 | Aug 8, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $187 → $180 | $126.96 | +41.78% | 22 | Aug 8, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $108 → $102 | $69.17 | +47.46% | 28 | Jul 31, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $99 → $102 | $66.34 | +53.75% | 31 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $121 → $124 | $69.79 | +77.68% | 26 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $328 → $360 | $224.66 | +60.24% | 27 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $204 → $185 | $175.40 | +5.47% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $160.27 | +68.47% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $10.67 | -6.28% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $109.23 | +148.10% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.65 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.91 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $83.56 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.08 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $88.24 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $6.31 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $75.15 | +14.44% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.27 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.01 | - | 3 | Jan 2, 2018 |
Axogen
Oct 30, 2025
Maintains: Outperform
Price Target: $20 → $27
Current: $32.84
Upside: -17.78%
Intuitive Surgical
Oct 22, 2025
Maintains: Outperform
Price Target: $592 → $603
Current: $483.46
Upside: +24.73%
CeriBell
Oct 21, 2025
Initiates: Strong Buy
Price Target: $19
Current: $19.16
Upside: -0.84%
Abbott Laboratories
Oct 16, 2025
Maintains: Outperform
Price Target: $141 → $146
Current: $109.95
Upside: +32.79%
Johnson & Johnson
Oct 15, 2025
Maintains: Outperform
Price Target: $174 → $209
Current: $243.19
Upside: -14.06%
Zimmer Biomet Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $104 → $113
Current: $93.30
Upside: +21.11%
ICU Medical
Aug 8, 2025
Maintains: Strong Buy
Price Target: $187 → $180
Current: $126.96
Upside: +41.78%
Merit Medical Systems
Jul 31, 2025
Maintains: Outperform
Price Target: $108 → $102
Current: $69.17
Upside: +47.46%
DexCom
Jul 31, 2025
Maintains: Strong Buy
Price Target: $99 → $102
Current: $66.34
Upside: +53.75%
Boston Scientific
Jul 24, 2025
Maintains: Strong Buy
Price Target: $121 → $124
Current: $69.79
Upside: +77.68%
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $224.66
Upside: +60.24%
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $175.40
Upside: +5.47%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $160.27
Upside: +68.47%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $10.67
Upside: -6.28%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $109.23
Upside: +148.10%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.65
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $21.91
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $83.56
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.08
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $88.24
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $6.31
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $75.15
Upside: +14.44%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.27
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $9.01
Upside: -